Iain Stuart - 13 Dec 2023 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: Chief Scientific Officer
Signature: /s/ Mutya Harsch, attorney-in-fact for Iain Stuart
Issuer symbol: VYNE
Transactions as of: 13 Dec 2023
Net transactions value: $0
Form type: 4
Filing time: 15 Dec 2023, 17:10:21 UTC
Previous filing: 04 Oct 2023
Next filing: 03 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Award	$0	+62,500	+690%	$0.000000	71,555	13 Dec 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VYNE	Stock Option (right to buy)	Award	$0	+62,500		$0.000000	62,500	13 Dec 2023	Common Stock	62,500	$2.70	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2	The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
F3	The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.